biphalin and Opioid-Related-Disorders

biphalin has been researched along with Opioid-Related-Disorders* in 2 studies

Reviews

1 review(s) available for biphalin and Opioid-Related-Disorders

ArticleYear
Biphalin-A Potent Opioid Agonist-As a Panacea for Opioid System-Dependent Pathophysiological Diseases?
    International journal of molecular sciences, 2021, Oct-21, Volume: 22, Issue:21

    Biphalin, one of the opioid agonists, is a dimeric analog of enkephalin with a high affinity for opioid receptors. Opioid receptors are widespread in the central nervous system and in peripheral neuronal and non-neuronal tissues. Hence, these receptors and their agonists, which play an important role in pain blocking, may also be involved in the regulation of other physiological functions. Biphalin was designed and synthesized in 1982 by Lipkowski as an analgesic peptide. Extensive further research in various laboratories on the antinociceptive effects of biphalin has shown its excellent properties. It has been demonstrated that biphalin exhibits an analgesic effect in acute, neuropathic, and chronic animal pain models, and is 1000 times more potent than morphine when administered intrathecally. In the course of the broad conducted research devoted primarily to the antinociceptive effect of this compound, it has been found that biphalin may also potentially participate in the regulation of other opioid system-dependent functions. Nearly 40 years of research on the properties of biphalin have shown that it may play a beneficial role as an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent, and may also affect many physiological functions. This integral review analyzes the literature on the multidirectional biological effects of biphalin and its potential in the treatment of many opioid system-dependent pathophysiological diseases.

    Topics: Analgesics; Analgesics, Opioid; Enkephalins; Morphine; Opioid-Related Disorders; Pain; Receptors, Opioid

2021

Other Studies

1 other study(ies) available for biphalin and Opioid-Related-Disorders

ArticleYear
A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro.
    Peptides, 2010, Volume: 31, Issue:8

    Biphalin is a new type of opioid peptide analog with high analgesic potency that is over 1000-fold greater than morphine. Because of its less addictive nature, biphalin has been suggested as a prospective new analgesic drug. Its high analgesic activity may be related to synergic interaction with all three types of opioid receptors (mu, delta, and kappa). Earlier data implicating involvement of opioid receptors, particularly MOR (mu opioid receptor) and KOR (kappa opioid receptor), in cell cycle regulation prompted us to investigate the effect of biphalin and morphine on human glioma T98G cell proliferation in vitro. We have documented an inhibitory effect of biphalin on tumor cell growth related to a decreased proliferation rate, decline of cell ability to form colonies, and modulation of the Ki-67 proliferation index. Morphine displayed the opposite effect and triggered stimulation of T98G cell proliferation. Our experiments have shown that biphalin might constitute an alternative solution for morphine application in anti-pain and anti-cancer therapy.

    Topics: Analgesics, Opioid; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Design; Enkephalins; Glioblastoma; Humans; Immunohistochemistry; Ki-67 Antigen; Kinetics; Morphine; Neoplastic Stem Cells; Opioid-Related Disorders; Receptors, Opioid; Tumor Stem Cell Assay

2010